Cards to study 2 Flashcards

1
Q

when can informed consent form requirement be waived for emergency use?

A
  1. life-threatening situation
  2. obtaining consent isn’t feasible
  3. prospect of direct benefit
  4. investigator is making every effort to contact an LAR
  5. additional protections will be provided
  6. IRB has approved waiver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

can someone be an advocate for a ward for multiple children?

A

yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

can a ward have both an advocate and a guardian/parent acting on their behalf?

A

yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Does a consent form need to require the approximate number of subjects involved in the study?

A

No, this is optional

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Is it required to state that findings during the research will be provided to the subject on the informed consent form?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Who is an investigator?

A

person conducting the clinical investigation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Who initiates a clinical investigation but does not actually conduct it?

A

Sponsor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Who initiates and conducts, alone or with others, an investigation?

A

Sponsor-investigator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How many days does an IRB have to revise its registration?

A

within 90 days of the changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How many days does an IRB have to revise its registration if disbanning?

A

30 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how long is an IRB’s registration good for?

A

3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What does 21 CFR 312 cover?

A

investigational new drug application

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When is an investigation exempt from part 312?

A
  1. not being submitted to FDA for a new indication or significant change in the label
  2. no significant change in advertising for prescription drugs
  3. route or dose level change, or new patient population, doesn’t significantly increase risks
  4. still complies with IRB and other regulations/requirements
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What 4 products are exempt from 312?

A

blood grouping serum, reagant red blood cells, anti-human globulin, drugs meant solely for in vitro or lab research animal testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how long does the FDA have to approve or disapprove of an IND application?

A

30 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Is a study involving use of a placebo exempt from 312?

A

Can be, if the study does not otherwise require submission of an IND

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Can the FDA provide written notification of a hold to the sponsor?

A

yes, phone or in writing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Can the sponsor proceed with the study after a hold?

A

Not until the FDA says they can proceed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Per Nuremberg Code principle 4, experiments should be conducted to void what?

A

unnecessary physical and mental suffering and injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Per Nuremberg Code principle 7, what 3 things should subjects be protected against?

A

injury, disability, death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Per Nuremberg Code principle 8, who should conduct investigations?

A

scientifically qualified persons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Nuremberg Code principle 9 states a subject can end the experiment when he reaches what?

A

physical or mental state where continuation of study seems impossible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Nuremberg Code principle 10 states that investigators should be ready to do what at all times?

A

terminate experiment if there is probable cause to believe it will likely result in injury, disability, or death to a subject

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

When was the Nuremberg Code written?

A

1947

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are two publicized examples of ethical abuses in research?

A

Willowbrook Studies, 1956-70

Jewish Chronic Disease Hospital Study, 1963

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What happened in the Willowbrook Studies?

A

children with intellectual disabilities were deliberately infected with hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

In what study were liver cancer cells injected into cognitively impaired patients?

A

Jewish Chronic Disease Hospital Study

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

When was Tuskegee condcuted?

A

1932-1972

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What prompted the National Research Act to be passed?

A

Tuskegee, prisoner research, Willowbrook, and more

30
Q

When was the National Research Act passed?

A

1974

31
Q

When was the Belmont Report released?

A

1979

32
Q

Who wrote the Belmont Report?

A

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research

33
Q

According to Nuremberg Code principle 2, what should experiments yield?

A

fruitful results for the good of society

34
Q

Nuremberg says experiments should not be ___ and ___ (principle 2).

A

Random

Unnecessary in nature

35
Q

Nuremberg says the experiment should be ___ by other methods

A

unprocurable

36
Q

What does the Nuremberg Code say experiment design should be based on?

A

result of animal experimentation and a knowledge of the disease or problem under study

37
Q

how long do phase II studies generally take to complete?

A

1-3 years

38
Q

how long do phase III studies generally take to complete?

A

2-5 years

39
Q

what phase study studies a drug used by practicing physicians in the same manner as it would be used after marketing?

A

phase III

40
Q

what phase study makes comparisons between a new treatment and standard therapy or placebo?

A

phase III

41
Q

what phase studies look at short and long-term safety data, respectively?

A

phase II, phase III

42
Q

what are 3 characteristics of phase IV studies?

A
  1. post-marketing
  2. continue to assess therapeutic value
  3. monitor less common AE’s
43
Q

what phase study is generally performed in animals?

A

pre-clinical

44
Q

what is submitted by the sponsor after sufficient pre-clinical data is obtained?

A

an IND to begin research in human subjects

45
Q

do phase I studies evaluate efficacy?

A

no, only determine appropriate dose range with regard to safety and toxicity

46
Q

what is significant equity interest?

A

if a PI gets interest or stock, or other financial and equity interest, during the time of the study and 1 year following completion (usually more than $50K to PI and family)

47
Q

what is considered a significant payment to an investigator in a covered trial?

A

over $25k during the trial or up to 1 year after trial completion

48
Q

what does 21 CFR 812 cover?

A

investigational device exemptions

49
Q

Name 5 parts of an investigational device plan.

A

1) purpose
2) protocol
3) risk analysis
4) device description
5) monitoring procedures
6) labeling
7) consent materials
8) IRB info
9) other institutions
10) records and reports

50
Q

Name 5 parts of an investigational device plan.

A

1) purpose
2) protocol
3) risk analysis
4) device description
5) monitoring procedures
6) labeling
7) consent materials
8) IRB info
9) other institutions
10) records and reports

51
Q

What does ICH stand for?

A

international conference on harmonization

52
Q

What two institutions recommend SOPs for consistency, efficacy, etc.?

A

FDA, ICH

53
Q

according to 21 CFR 812, how long should records be kept at a site after study closure?

A

2 years

54
Q

according to 21 CFR 812, a sponsor can select a monitor that is qualified by what two things?

A

experience and training

55
Q

Do Health and Human services regulations apply under trials conducted under FDA regulations?

A

Yes

56
Q

Which phase is an aftermarket trial?

A

IV

57
Q

Which trial phase expands on the safety profile of a compound and further explores efficacy?

A

III

58
Q

Annual Reports of the study should be submitted to the FDA within ____ days of the anniversary date of the trial? Which regulation requires this?

A

60; 312

59
Q

According to 21 CFR 812, if an investigator uses a device without obtaining consent, they must report such use to the IRB within how many days?

A

5 working days

60
Q

what is the primary role of the IRB?

A

protect the rights and welfare of human subjects participating in clinical trials

61
Q

does the IB need IRB approval?

A

no

62
Q

Can 1 IRB member satisty more than 1 category?

A

yes

63
Q

FDA requires that all study records be retained for how long after a marketing application is approved?

A

2 years

64
Q

what document is the cornerstone of human research ethics?

A

declaration of helsinki

65
Q

what is the date of the declaration of helsinki?

A

1964

66
Q

what phase are dose escalation studies?

A

phase I

67
Q

what regulation covers both informed consent guidelines and additional protections children?

A

21 CFR 50

68
Q

what section of 21 CFR 312 covers disposition of unused study drug?

A

59

69
Q

Gaining FDA/IRB approval in advance, choosing investigators and monitors, monitoring investigations, and emergency research are all responsibilities of who? And per what regulation?

A

the sponsor; 21 CFR 812

70
Q

Awaiting approval, compliance, supervising device use, financial disclosure, and disposing of device are all responsibilities of who? And per what regulation?

A

the investigator; 21 CFR 812